We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- COPD exacerbations
- Airway bacteria - stable COPD & exacerbations (1)
- RCT of antibiotic therapy
- Sputum characteristics
- Bacterial eradication & inflammation
- Changes in bacterial load
- Risk of exacerbation & bacterial strain change
- Strain change & bacterial load relationship
- Lung microbiome in smoker vs. COPD (1)
- Lung microbiome in smoker vs. COPD (2)
- Respiratory viruses & exacerbation
- Exacerbation recovery after onset
- HRV and COPD exacerbations
- Effect of common colds on IL6 in induced sputum
- Plasma fibrinogen at exacerbation
- Exacerbation frequency & common cold in COPD
- Susceptibility of COPD patients to rhinovirus
- Eosinophilic markers of viral exacerbations
- Lower airway bacteria & rhinoviral infection
- Sputum IL1B at bacterial exacerbations
- Change in IP10 from baseline to exacerbation
- IP10 ROC curve analysis
- Airway bacteria - stable COPD & exacerbations (2)
- Bacterial load & airway inflammation
- Airway bacterial load & FEV1 decline
- Lower lobe bronchiectasis - COPD & inflammation
- Doxycycline vs. placebo (1)
- Doxycycline vs. placebo (2)
- Exacerbation frequency & bacterial colonization
- Long term antibiotics
- Patients with purulent/mucopurulent sputum
- Macrolides - time to 1st exacerbation
- Macrolides - sputum markers
- Macrolide (Azithromycin) study
- Macrolide study - subgroup analysis
- RSV infection in stable COPD
- Patterns of RSV infection
- RSV & FEV1 decline
- High sputum myeloperoxidase in COPD with RSV
- Conclusion
Topics Covered
- Roles of viral and bacterial infections at exacerbations of COPD
- Airway bacteria
- RCT of antibiotic therapy
- Sputum characteristics
- Bacterial eradication & inflammation
- Bacterial strain change
- Lung microbiome in smoker vs. COPD
- Plasma fibrinogen at exacerbation
- Exacerbation frequency & common cold in COPD
- Rhinovirus
- Eosinophilic markers of viral exacerbations
- Lower lobe bronchiectasis
- Doxycycline vs. placebo
- Long term antibiotics
- Patients with purulent/mucopurulent sputum – Macrolide studies
- RSV infection in COPD
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Wedzicha, W. (2013, July 11). The role of infection at COPD exacerbations [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 3, 2024, from https://doi.org/10.69645/KJGU9442.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Wisia Wedzicha has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.